1. Knapp Jr., F.F.: Use of Re-188 for cancer treatment. Can. Biother. Radiopharm. 13, 337–349 (1998)
2. Liepe, K., Kropp, J., Hliscs, R., Runge, R., Knapp Jr, F.F., Franke, W.-G.: Dosimetry of 188-Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J. Nucl. Med. 44, 953–960 (2003)
3. Kodina, G., Tulskaya, T., Gurcev, E., Brodskaya, G., Gapurov, O., Drosdovsky, B.: Production and investigation of Rhenium-188 generator in Technetium and Rhenium. In: Nicolini, M., Bandoli, G., Mazzi, U. (eds.) Chemistry and Nuclear Medicine, vol. 3, pp. 635–641. Cortina International, Verona, Italy - Raven Press, New York (1990)
4. Zhang, H., Tian, M., Li, S., Tanada, S., Endo, K.: Re-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Can. Biother. Radiopharm.18, 719–726 (2003)
5. Miao, Y., Owen, N.K., Whitener, D., Gallazzi, F., Hoffman, T.J., Quinn, T.P.: In vivo evaluation of 188Re labeled alpha-melatocyte stimulating hormone peptide analogs for melanoma therapy. Int. J. Cancer. 101, 480–487 (2002)